web analytics
0.3 C
Munich
Saturday, December 3, 2022

Halberd Corporation (OTCMKTS: HALB) Reversing Northbound as Biotech Creates Methodology for Eradicating Gram-Negative Bacteria

Halberd Corporation (OTCMKTS: HALB) is making a run after the Company announced it has successfully eliminated various antibiotic resistant bacteria from buffer solution in-vitro through the use of a single designer monoclonal antibody conjoined to a metallic nanoparticle which attaches to the bacteria. The combined bacteria-antibody-nanoparticle cluster are then exposed to laser emissive energy. In lab testing, over 90% of each bacteria was eliminated in less than 20 minutes. With the current patient standard of care using broad spectrum antibiotics, similar results can take up to 10 days, during which major organ damage or death can occur. 

HALB is moving northbound since a brief dip below a penny following months of declines since the stock spiked over $0.10 in early 2021. Currently under accumulation HALB trades at a $5 million market valuation and has a clean balance sheet with minimal assets or revenues and just $600,000 in total liabilities. We first reported on HALB back in September 2020 stating at the time: “HALB holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” and “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus.” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.”  


Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Halberd Corporation (OTC Pink: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners. 

In 2020 the Company acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus’. The issued patents’ extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. 

The Company has developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. 

Earlier this year HALB entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”. The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease and Cancer treatments using the combined patented and patent-pending technologies of the alliance member companies. The subsidiary will be staffed by personnel from all three entities for the purpose of developing and combining Halberd’s patented extracorporeal technology for the elimination of target disease antigens with AI Longevity’s work to date which has identified several bio-factors, markers and antigens which contribute to aging, with Stem of Hope’s stem cell research in disease treatment.  

To Find out the inside Scoop on HALB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HALB

On October 18 HALB announced it has successfully eliminated various antibiotic resistant bacteria from buffer solution in-vitro through the use of a single designer monoclonal antibody conjoined to a metallic nanoparticle which attaches to the bacteria. The combined bacteria-antibody-nanoparticle cluster are then exposed to laser emissive energy. In lab testing, over 90% of each bacteria was eliminated in less than 20 minutes. 

With the current patient standard of care using broad spectrum antibiotics, similar results can take up to 10 days, during which major organ damage or death can occur. Additionally, potential risks and adverse reactions are common factors with the use of antibiotics. 

Through cooperation with their research partners at Arizona State University and Youngstown State University, Halberd Corporation created a methodology for eradicating Gram-negative bacteria, such as E. coli, Salmonella and Shigella. Gram-negative bacteria (GNB) are characterized by their high resistance to antibiotics.1 

Halberd is able to perform this eradication in a few minutes using its extra-corporeal technique. The proprietary designer monoclonal antibody is an antibody against a common antigen which is encountered with all Gram-negative bacteria. The conjoined antibody-metallic nanoparticle is attracted to, and attaches to, Gram-negative bacteria cells, which are then rapidly annihilated by a laser. 

Dr. Mitchell S. Felder, Halberd’s Chief Technology Officer and board-certified attending neurologist, stated, “It is my opinion that this may prove to be the greatest advancement in the field of infectious diseases since the invention of Penicillin by Sir Alexander Fleming in 1928. This technology could allow for the rapid, inexpensive eradication of any and all Gram-negative bacteria, no matter how pathogenic, without any possibility of resistance by the infectious agent. This could be a very major breakthrough against Gram-negative bacterial sepsis, which kills millions of people worldwide each year.” 
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, “I agree with Dr. Felder. This technological achievement is truly ground-breaking! This is another application of our patented extracorporeal method for treating virtually any disease. The CDC has indicated that it will provide a broad spectrum of antibiotic-resistant bacteria samples for research. With those samples we intend to further prove the efficacy of our proprietary antibody against these hardy bacteria. We will continue to report on the progress of our outstanding achievements in this area.” 

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $5.2 million market valuation HALB OS is 515,874,842 shares with 280,542,712 shares in the float. The Company is an SEC filer and has a clean balance sheet with just $600k in total liabilities. HALB is an exciting story in small caps that we have been reporting on since September 2020; the Company is building a valuable patent portfolio and has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications. At just over a penny and highs over $0.10 in 2021 HALB is one biotech that deserves to penny stock speculators watch lists now that it has reversed northbound since a brief dip below a penny. We will be updating HALB as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with HALB.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HALB either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.